Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Peter G S Mortimer"'
Autor:
Simon Smith, Woong-Yang Park, Kyoung-Mee Kim, Jeeyun Lee, Jung Yong Hong, Seung Tae Kim, Won Ki Kang, Emma Dean, Minsuk Kwon, Gahyun Kim, Ryul Kim, Kyu-Tae Kim, Peter G S Mortimer, Arsene-Bienvenu Loembé, Itziar Irurzun-Arana, Loumpiana Koulai
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 7 (2022)
Background Targeting the DNA damage repair (DDR) pathways is an attractive strategy for boosting cancer immunotherapy. Ceralasertib (AZD6738) is an oral kinase inhibitor of ataxia telangiectasia and Rad3 related protein, which is a master regulator o
Externí odkaz:
https://doaj.org/article/0fb079375db848879a747baa38eb0c19
Autor:
Koung Jin Suh, Min-Hee Ryu, Dae Young Zang, Woo Kyun Bae, Hye Seung Lee, Hyeon Jeong Oh, Minsu Kang, Ji-Won Kim, Bum Jun Kim, Peter G S Mortimer, Hee Jung Kim, Keun-Wook Lee
Publikováno v:
The Oncologist.
Background Loss of PTEN function leads to increased PI3Kβ signaling. AZD8186, a selective PI3Kβ/δ inhibitor, has shown anti-tumor activity in PTEN-deficient preclinical models. Although the combination of AZD8186 and paclitaxel was well tolerated,
Autor:
Minsuk Kwon, Gahyun Kim, Ryul Kim, Kyu-Tae Kim, Seung Tae Kim, Simon Smith, Peter G S Mortimer, Jung Yong Hong, Arsene-Bienvenu Loembé, Itziar Irurzun-Arana, Loumpiana Koulai, Kyoung-Mee Kim, Won Ki Kang, Emma Dean, Woong-Yang Park, Jeeyun Lee
Publikováno v:
Journal for ImmunoTherapy of Cancer. 10:e005041
BackgroundTargeting the DNA damage repair (DDR) pathways is an attractive strategy for boosting cancer immunotherapy. Ceralasertib (AZD6738) is an oral kinase inhibitor of ataxia telangiectasia and Rad3 related protein, which is a master regulator of
Autor:
Melanie M, Frigault, Aleksandra, Markovets, Barrett, Nuttall, Kyoung-Mee, Kim, Se Hoon, Park, Esha A, Gangolli, Peter G S, Mortimer, Simon J, Hollingsworth, Jung Yong, Hong, Kyung, Kim, Seung Tae, Kim, J Carl, Barrett, Jeeyun, Lee
Publikováno v:
JCO Precision Oncology
PURPOSE Some gastric cancers harbor MET gene amplifications that can be targeted by selective MET inhibitors to achieve tumor responses, but resistance eventually develops. Savolitinib, a selective MET inhibitor, is beneficial for treating patients w
Publikováno v:
Journal of Antimicrobial Chemotherapy. 32:195-213
A library of isogenic mutants containing Mud9-induced deletions of the structural and regulatory genes for the porin proteins OmpF and OmpC of Escherichia coli was constructed. The accumulation of norfloxacin, tetracycline, chloramphenicol, cephaloth